Keratoacanthoma
☆ Liphethong tsa 2022 Stiftung Warentest tse tsoang Jeremane, khotsofalo ea bareki ka ModelDerm e ne e le tlase hanyane ho feta lipuisano tse lefelloang tsa telemedicine.
E tloaelehileng Keratoacanthoma
References
Keratoacanthoma (KA) ke hlahala khafetsa letlalong e tsebahalang ka ho hola ka potlako le monyetla oa ho khutla ka bo eona. Hangata e etsahala ho banna ba hōlileng, ba letlalo le letle ba nang le histori ea ho senyeha ha letsatsi. Le hoja ho tlosoa ha opereishene ho sebelisoa excision kapa Mohs micrographic opereishene e le phekolo e tloaelehileng, ho na le mekhoa e meng ea phekolo e fumanehang.
Keratoacanthoma (KA) is a common cutaneous tumor characterized by rapid growth and possible spontaneous regression. It most commonly affects older, fair-skinned males with significantly sun damaged skin. Although surgical removal with excision or Mohs micrographic surgery remains the standard of therapy, there are many alternative therapeutic modalities that can be utilized.
Keratoacanthoma (KA) is a common cutaneous tumor characterized by rapid growth and possible spontaneous regression. It most commonly affects older, fair-skinned males with significantly sun damaged skin. Although surgical removal with excision or Mohs micrographic surgery remains the standard of therapy, there are many alternative therapeutic modalities that can be utilized.
Keratoacanthoma (KA) ke hlahala ea boemo bo tlaase e qalang litšoelesa tse itseng letlalong 'me e tšoana le squamous cell carcinoma (SCC) tlas'a microscope. Ho na le phehisano e ntseng e tsoela pele mabapi le hore na KA e lokela ho hlalosoa e le mofuta oa SCC e hlaselang.
Keratoacanthoma (KA) is a comparatively common low-grade tumor that initiates in the pilo-sebaceous glands and pathologically mimics squamous cell carcinoma (SCC). Essentially, strong debates confirm classifying keratoacanthoma as a variant of invasive SCC. The clinical behavior of KA is hardly predictable and the differential diagnosis of keratoacanthoma and other conditions with keratoacanthoma-like pseudocarcinomatous epithelial hyperplasia is challenging, both clinically and histopathologically.
Keratoacanthoma (KA) is a comparatively common low-grade tumor that initiates in the pilo-sebaceous glands and pathologically mimics squamous cell carcinoma (SCC). Essentially, strong debates confirm classifying keratoacanthoma as a variant of invasive SCC. The clinical behavior of KA is hardly predictable and the differential diagnosis of keratoacanthoma and other conditions with keratoacanthoma-like pseudocarcinomatous epithelial hyperplasia is challenging, both clinically and histopathologically.
Cutaneous squamous cell carcinoma (cSCC) ke mofuta oa bobeli o atileng haholo oa mofetše ho batho, haholo har'a batho ba baholo. Hangata ho buuoa ho sebelisoa ho phekola cSCC, empa ho bakuli ba bang ba sa khoneng ho buuoa kapa ba khethang ho se etse, mekhoa e meng e kang phekolo ea intralesional e ka nkoa. Liphekolo tsa setso tsa intralesional (methotrexate or 5-fluorouracil) li se li sebelisitsoe, empa ho na le lipatlisiso tse tsoelang pele mabapi le mekhoa e mecha joalo ka intralesional immunotherapy le oncolytic virotherapy. Mona, re tla sheba mefuta e fapaneng ea kalafo ea intralesional bakeng sa cSCC, ho tloha mekhoeng ea khale ho isa ho maano a sejoale-joale.
Cutaneous squamous cell carcinoma (cSCC) is the second most frequent cancer in humans, and it is especially common in fragile, elderly people. Surgery is the standard treatment for cSCC but intralesional treatments can be an alternative in those patients who are either not candidates or refuse to undergo surgery. Classic intralesional treatments, including methotrexate or 5-fluorouracil, have been implemented, but there is now a landscape of active research to incorporate intralesional immunotherapy and oncolytic virotherapy into the scene, which might change the way we deal with cSCC in the future. In this review, we focus on intralesional treatments for cSCC (including keratoacanthoma), from classic to very novel strategies.
Cutaneous squamous cell carcinoma (cSCC) is the second most frequent cancer in humans, and it is especially common in fragile, elderly people. Surgery is the standard treatment for cSCC but intralesional treatments can be an alternative in those patients who are either not candidates or refuse to undergo surgery. Classic intralesional treatments, including methotrexate or 5-fluorouracil, have been implemented, but there is now a landscape of active research to incorporate intralesional immunotherapy and oncolytic virotherapy into the scene, which might change the way we deal with cSCC in the future. In this review, we focus on intralesional treatments for cSCC (including keratoacanthoma), from classic to very novel strategies.
Ka tlas'a microscope, keratoacanthoma e tšoana haholo le squamous cell carcinoma. Le hoja litsebi tse ling tsa pathology li khetholla keratoacanthoma e le ntho e ikhethang eseng lefu le bolaeang, hoo e ka bang 6% ea kliniki le histological keratoacanthoma e tsoela pele ho ba le kankere e hlaselang le e mabifi ea squamous cell.
○ Tlhahlobo le Kalafo
#Dermoscopy
#Skin biopsy